Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Phaos Technology Holdings Cayman Debt-to-EBITDA?
Phaos Technology Holdings CaymanPOAS -6.08%4 Debt-to-EBITDA is -0.06 as of Oct. 2025. GuruFocus rates POAS with a GF Score™ of 4/100. The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Phaos Technology Holdings Cayman ranks worse than 213675% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Phaos Technology Holdings Cayman's Debt-to-EBITDA or its related term are showing as below:
POAS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61 Med: -0.37 Max: -0.04
Current: -0.04
During the past 3 years, the highest Debt-to-EBITDA Ratio of Phaos Technology Holdings Cayman was -0.04. The lowest was -0.61. And the median was -0.37.
POAS's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs POAS: -0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Phaos Technology Holdings Cayman Debt-to-EBITDA Related Terms
Phaos Technology Holdings Cayman Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POAS vs WOK, ITOC, INBS: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Phaos Technology Holdings Cayman's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phaos Technology Holdings Cayman Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Phaos Technology Holdings Cayman's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Phaos Technology Holdings Cayman's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Oct. 2025) EBITDA data.
Phaos Technology Holdings Cayman (POAS) has a Debt-to-EBITDA of -0.06 as of Oct. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Phaos Technology Holdings Cayman. According to the industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is Phaos Technology Holdings Cayman's Debt-to-EBITDA too high?
Phaos Technology Holdings Cayman's current Debt-to-EBITDA is -0.06. Based on the distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Phaos Technology Holdings Cayman has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Phaos Technology Holdings Cayman's Debt-to-EBITDA compare to WOK and ITOC?
According to the Medical Devices & Instruments industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 468 companies for Debt-to-EBITDA. This places Phaos Technology Holdings Cayman in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Phaos Technology Holdings Cayman. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phaos Technology Holdings Cayman's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phaos Technology Holdings Cayman stock overvalued right now?
Phaos Technology Holdings Cayman (POAS) has a current Debt-to-EBITDA of -0.06. The current Debt-to-EBITDA is -0.06. Phaos Technology Holdings Cayman's overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Phaos Technology Holdings Cayman (POAS), the current Debt-to-EBITDA is -0.06 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phaos Technology Holdings Cayman Business Description
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
4GF Score
Get the complete analysis for POAS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POAS has been successfully added to your 
